Loading...
•
Sep 30, 2023
Replimune Q2 2024 Earnings Report
Announced financial results for the fiscal second quarter ended September 30, 2023 and provided a business update.
Key Takeaways
Replimune Group, Inc. reported financial results for the fiscal second quarter ended September 30, 2023. The company is planning to present topline data from the CERPASS clinical trial and an initial snapshot from the IGNYTE clinical trial cohort. They are also excited to present the design of a confirmatory study agreed with the FDA to support a potential approval of RP1 in anti-PD1 failed melanoma via the accelerated approval pathway.
Presenting topline data from CERPASS clinical trial of RP1 in combination with Libtayo in cutaneous squamous cell carcinoma (CSCC).
Sharing an initial snapshot from the IGNYTE clinical trial cohort of RP1 combined with Opdivo in anti-PD1 failed melanoma.
Presenting the design of a confirmatory study agreed with the FDA to support a potential approval of RP1 in anti-PD1 failed melanoma via the accelerated approval pathway.
Continuing to see anti-tumor activity in Phase 1 program for RP2 and RP3 with a full update expected in early 2024.
Replimune
Replimune
Forward Guidance
Based on the current operating plan, the Company believes that existing cash, cash equivalents and short-term investments, as of September 30, 2023, will enable the Company to fund operations into the second half of calendar year 2025.